secwatch.observer — SEC 8-K summary
======================================

Issuer:     MeiraGTx Holdings plc (MGTX)
CIK:        0001735438
Form:       8-K
Filed at:   2024-02-13T23:59:59+00:00
Accession:  0001558370-24-001020
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MeiraGTx receives $50M milestone from Janssen for bota-vec Phase 3 extension study
--------------------------------------------------------------------------------

- $50M milestone triggered by initiation of LUMEOS extension study for bota-vec (XLRP gene therapy).
- Additional $15M in near-term milestone payments expected later in 2024 from Janssen.
- Up to $285M further payments on first U.S./EU commercial sales and manufacturing tech transfer.
- Commercial supply agreement with J&J for bota-vec manufacturing expected to generate ongoing revenue.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1735438/000155837024001020/0001558370-24-001020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1735438/000155837024001020/mgtx-20240213x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-001020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer